Weir, Matthew R.

Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern?

Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 823

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Shlipak, M. G., Tummalapalli, S. L., Boulware, L. E., Grams, M. E., Ix, J. H., Jha, V., Kengne, A.-P., Madero, M., Mihaylova, B., Tangri, N., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 581

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 498

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 441

American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 358

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 219

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

Kasiske, B. L., de Mattos, A., Flechner, S. M., Gallon, L., Meier-Kriesche, H.-U., Weir, M. R., & Wilkinson, A. (2008) · American Journal of Transplantation

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and Outcomes

Cited by 163

THE PROGNOSTIC VALUE OF THE EOSINOPHIL IN ACUTE RENAL ALLOGRAFT REJECTION

WEIR, M. R., HALL-CRAGGS, M., SHEN, S. Y., POSNER, J. N., ALONGI, S. V., DAGHER, F. J., & SADLER, J. H. (1986) · Transplantation

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and Outcomes

Cited by 69

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.

Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 56

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021) · Clinical Kidney Journal

Diabetes Treatment and ManagementPotassium and Related Disorders

Cited by 31

Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

Weir, M. R., & Bakris, G. L. (2010) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 26

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12